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SUMMARY. To explore healthcare costs associated with
antiviral treatment of hepatitis B virus (HBV) in Turkey.
Research-identified data from a claims processing system
for all Turkish health insurance funds were analysed.
Adult patients prescribed oral antiviral and pegylated
interferon treatment were identified between 1 January
2010 and 31 December 2010. The first prescription date
was defined as the index date. Patients were required to
have HBV diagnosis within the 6-month pre-index period.
Pharmacy, outpatient and inpatient claims were compiled
over the study period for the selected patients, and risk-
adjusted 1-year healthcare costs of patients with oral an-
tiviral and pegylated interferon treatment were compared.
Risk adjustment was carried out using propensity score
matching, controlling for baseline demographic and clini-
cal characteristics. A total of 9618 patients were identified,
of which 9074 were treated with oral antiviral medication
and 544 with pegylated interferon medication. The oral
antiviral treatment group was older (45.28 vs 42.19,
P < 0.001), less likely to be female (32.17% vs 39.71%,
P < 0.001) and to reside in Southeastern Anatolia (8.29%
vs 13.97%, P < 0.001) or Mediterranean region (8.90% vs
11.76%, P < 0.03) and had higher Elixhauser comorbidity
index scores (60.22% vs 74.08%, P < 0.001) than the
pegylated interferon group. After adjusting for confounding
factors, total medical costs for pegylated interferon patients
were €2771 higher than for oral antiviral patients
(P < 0.001), due to higher outpatient and prescription
costs. For annual healthcare costs for antiviral treatment
options for HBV patients in Turkey, after adjusting for age,
gender, region and comorbid condition differences, oral
antiviral treatment is more costly than pegylated inter-
feron treatment.
Keywords: hepatitis b, medical costs, outcomes research,
real-word data analysis.
INTRODUCTION
Hepatitis B virus (HBV) is a major global health problem.
According to 2009 World Health Organization (WHO) esti-
mates, >2 billion people have been exposed to HBV [1].
378 million are chronically infected worldwide [2].
Approximately 600 000 deaths each year are associated
with acute and chronic consequences of hepatitis B. HBV
infection is the leading cause of chronic hepatitis and cir-
rhosis worldwide, and approximately 40% of all chronic
hepatitis B (CHB) patients will develop cirrhosis, liver
failure or hepatocellular carcinoma (HCC) [3].
According to WHO classification, Turkey is an intermedi-
ate (2–8%) endemic country for HBV seropositivity, with
varying rates from west to east regions (from 2–4% to 3.9–
12.5%, respectively) [4–6]. In intermediate endemic areas,
the most common routes of HBV transmission are believed
to be mother-to-child and horizontal transmission via close
contact [5]. According to the Ministry of Health report of
2003 in Turkey, almost one-third of the population in Turkey
has already been infected with HBV; 3–4 million are carriers
and nearly 350 cases of HCC have been reported [7].
The natural course of HBV infection has a great spec-
trum from a chronic carrier state, chronic active hepatitis
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and cirrhosis, after acute exposure [8]. The possibility of
chronic HBV infection is higher for newborns, in whom
the exposure occurs during pregnancy or delivery, and the
lowest is for adults. Most acute HBV infections lead to
spontaneous hepatitis B surface antigen (HBsAg; a marker
of communicability) clearance in adults [9].
In 1998, a national vaccination programme was
launched to prevent prenatal transmission of HBV in Tur-
key. The prevalence of HBsAg positivity has dropped from
4.19% to 2.10%, with the help of the programme [4,10].
However, the economic burden of HBV is substantial
because of the long-term effects of HBV infection on the
liver. Over $1 billion is spent annually for HBV-related
hospitalizations [11]. For instance, in the United States, the
trend in economic burden reflects a considerable increase
in the last decade [12], with estimated HBV-related hospi-
talization costs increasing from $357 million in 1990 to
$1.5 billion in 2003 [12]. The primary reasons for the rise
in HBV-related healthcare costs are increased outpatient
visits and hospitalizations, more expensive diagnostic tools
and new therapeutic options for HBV-positive patients.
Akarsu et al. [13] evaluated the relationship between
aetiological groups and costs and determined that the
highest costs were incurred among HBV and HCC patients
with 75% HBV-positivity.
Significant progress has been made in antiviral HBV
treatment, capable of effectively suppressing viral replica-
tion in 95% of cases of CHB [14]. The main goals of
HBV treatment are to prevent cirrhosis, hepatic decompo-
sition and HCC, thereby improving mortality and morbid-
ity rates and quality of life by preventing disease
progression [14]. Two available treatment approaches
consist of either stimulating the immune system through
pegylated interferon or suppressing viral load through
nucleotide analogues (lamivudine, adefovir, entecavir, tel-
bivudine and tenofovir) [14,15]. It has been well docu-
mented that oral antiviral drugs are generally better
tolerated and suppress HBV viral load more effectively
than pegylated interferon therapy, but must have longer
duration of use [16]. Therefore, in this study using
national claims data, comparative effectiveness research
was designed to inform healthcare decision-makers by
providing evidence of total healthcare costs of HBV
patients who were prescribed oral antiviral and pegylated
interferon therapy.
MATERIALS AND METHODS
In 2006, Turkey began a social security and health system
under the Social Security Institute (SSI). Mandatory enrol-
ment is required for the current Universal Health Insur-
ance (UHI) Fund within the SSI. Insurance contribution
rates are determined proportionally to a patient’s ability to
pay, and all beneficiaries are entitled to the same benefit
package.
In Turkey, payment by health insurance fund is based
both on a retrospective fee-for-service (FFS) and bundled
payment system, depending on disease category and ser-
vices related to the particular disease. Payment procedures
are outlined by health budget laws (Saglık Uygulama
Tebligi or S€UT). University hospitals are paid based on the
FFS system. Private hospitals, however, are generally paid
according to the bundled payment system. Laboratory
services can be paid separately through the bundled pay-
ment system, based on certain conditions. Access to CHB
drugs is determined by Ministry of Health protocol, and
payment is determined by the health budget laws of the
SSI. These protocols and health budget laws describe under
what conditions, how much and which patients should be
prescribed these medications.
Data for this study were obtained from MEDULA, a
nationwide medical information collection system in Turkey,
which was established under the 2007 Health Budget Law.
The research-identified MEDULA data set is comprised of
pharmacy, inpatient, outpatient and laboratory claims and
encompasses 17 800 pharmacies, 5600 general practitio-
ners, 4500 medical centres, 1200 government hospitals and
338 private hospitals, covering more than 80% of the popu-
lation in Turkey. The remaining 20% of the population not
included in the data consists of those whose contribution
rates were paid by the government due to their income level.
These data were maintained separately from the UHI Fund
in the SSI until 2012. Moreover, members of the Turkish
Grand National Assembly and the Supreme Court as well as
foreign insurance holders and some military personnel were
excluded from the UHI Fund in the SSI. The data have been
used in several outcomes research studies [17–21].
In this retrospective analysis, the study period was from
1 July 2009 through 31 December 2011. Oral antiviral
and pegylated interferon therapy use during the identifica-
tion period (1 January 2010–31 December 2011) was first
identified. The first prescription date was designated as the
index date. All patients were required to be continuously
enrolled during the 6-month pre-index (baseline) period
and 12-month postindex (follow-up) period. Using appro-
priate diagnosis codes from the International Classification
of Diseases Tenth Revision Clinical Modification (ICD-10-
CM), all patients with chronic or active HBV in the pre-
index period were included in the study. Patients under
18 years of age, who were pregnant, diagnosed with
human immunodeficiency virus (HIV) infection, underwent
immunosuppressive or cancer therapy, had history of cir-
rhosis or chronic liver failure, hepatitis C or delta hepatitis
during the 6-month pre- and 12-month postindex periods
were excluded from the analysis (Fig. 1).
Demographic factors such age, gender and region were
available in the data. To control for clinical characteristics,
we calculated a comorbidity index score for each patient
for the baseline period, using the Elixhauser method [22].
The index has been widely used, because it differentiates
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comorbid complications by excluding the codes that reflect
acute conditions. For example, pneumonia, pleural effu-
sion, urinary tract infection, cardiac arrest, cardiogenic
shock and respiratory failure were not counted as comor-
bidities because they are not distinguishable from compli-
cations that may have resulted from diagnostic or
therapeutic interventions during hospitalization. Comorbid-
ities such as benign prostatic hypertrophy, inguinal hernia
and diverticulitis were not included, because they do not
impact resource use or mortality if they were not principle
diagnosis. Current coding for the Elixhauser index is avail-
able from the Agency for Healthcare Research and Quality
(AHRQ) [23]. Individual comorbidities such as essential
hypertension, type 2 diabetes and atherosclerotic heart
disease of native coronary artery were also identified.
Reimbursement amounts were available in the data, and
the annual costs were separated by inpatient, outpatient
and pharmacy costs and copays.
Causal inference is challenging in all nonexperimental
studies because of the possibility of overt bias. When evalu-
ating certain treatment groups, overt bias can occur as treat-
ment and control groups differ in terms of observable factors
such as age, gender, region and comorbidities. To eliminate
overt bias in the current study, propensity score matching
(PSM) was applied to compare healthcare costs associated
with oral antiviral and pegylated interferon use. PSM
employs the predicted probability of group membership and
isolates the observed bias from the estimation [24]. Specifi-
cally, a patient’s propensity score is the probability of being
treated based on the condition of the patient’s covariate val-
ues, such as demographic and clinical factors. If two
patients, one in the oral antiviral and the other in the pegy-
lated interferon group, with the same or similar propensity
score, these subjects can be considered similar for all
observed factors that are controlled to predict probability.
The only difference is that one patient used oral antiviral
treatment and the other pegylated interferon. Consequently,
all outcomes (costs, utilization) of the matched group are
due to treatment only and not other factors, such as age,
gender and comorbiditiesc. Following the guidelines to
choose the most appropriate matching technique for study
data, radius, kernel, mahalanobis and one-to-one matching
were compared and ultimately one-to-one matching was
applied [25]. Patient age, gender, region, Elixhauser index
score and baseline individual comorbidities were used as
explanatory variables in the PSM model.
The analysis was conducted using SAS V.9.3 (SAS Insti-
tute Inc., Cary, NC, USA) and STATA V11 software (Stata-
Corp LP, College Station, TX, USA).
RESULTS
A total of 9074 patients in the oral antiviral group and
544 in the pegylated interferon group satisfied all inclusion
and exclusion criteria (Fig. 2) and were included in the
study population.
Patients in the oral antiviral group were older (45.28 vs
42.19, P < 0.001), less likely to be female (32.17% vs
39.71%, P < 0.001) and reside in the Southeastern Anatolia
(8.29% vs 13.97%, P < 0.001) or Mediterranean regions
(8.90% vs 11.76%, P < 0.030), relative to those in the pegy-
lated interferon group. Patients prescribed pegylated interferon
medication had higher Elixhauser comorbidity index scores
than those prescribed oral antiviral medications (60.22% vs
74.08%, P < 0.001). There were no significant differences in
individual comorbid conditions such as hypertension, diabetes
and heart disease between the two groups (Table 1).
The primary objective was to compare total healthcare
costs between HBV patients prescribed oral antiviral and
pegylated interferon medications. Because descriptive com-
parison of costs would be confounded by the differences in
age, gender, region and comorbidity index scores, as
outlined in the previous paragraph, PSM was employed.
Table 2 presents the results after PSM. A total of 544
patients in the pegylated interferon group were matched
with comparable patients in the oral antiviral group in
terms of age, gender, region, comorbidity index score and
individual comorbidities. As presented in P-values in
Table 2, after matching, there were no significant differ-
ences in the observed baseline characteristics.
Over the matched sample, annual healthcare costs after
medication use between the two groups were calculated
Fig. 1 Description of study period.
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and compared. This risk-adjusted comparison isolates the
differences in terms of the demographic and clinical
characteristics outlined in Tables 1 and 2.
Annual risk-adjusted total medical costs for patients with
pegylated interferon use were €5729. Costs were signifi-
cantly higher than for patients prescribed oral antiviral
Fig. 2 Inclusion and exclusion criteria of the HBV patient study sample.
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medications (€2958, P < 0.001). Although there were no
significant differences between inpatient costs and copays,
outpatient (€588 vs €334, P < 0.001) and pharmacy costs
(€2554 vs €4965, P < 0.001) were significantly higher for
patients with pegylated interferon use vs oral antiviral use
(Table 3).
DISCUSSION
Comparative effectiveness data determine trade-offs driven
by different cost profiles among treatment options, and sec-
ondary databases provide a valuable source of information
for healthcare solutions.
The current study, using national health insurance data
in Turkey, compared the annual costs of HBV patients pre-
scribed oral antiviral and pegylated interferon therapy.
Although oral antiviral drugs were better tolerated and
suppressed HBV viral load values more effectively, longer
duration of use relative to pegylated interferon therapy cre-
ated ambiguous cost-effectiveness results. There are most
likely two main reasons why oral antiviral drugs are less
expensive. First, there are only two medications that con-
sisted of pegylated interferon in our study, and the number
of marketed oral antiviral agents is five with perhaps three
to four times as many generic agents available in Turkey.
Second, the technologies used to produce interferon and
oral antiviral agents are quite different. It is probably more
difficult and expensive to produce interferon.
Previously, in a cost-effectiveness analysis of CHB treat-
ment in Turkey, Toy et al. [3] reported that annual costs
of pegylated interferon alfa-2a were €9624 compared with
lamivudine (€585), adefovir (€5976), entecavir (€5618)
and tenofovir (€3994). However, this study was based on
Markov cohort analysis using a database of two reference
hospitals in Ankara, Turkey. The natural history of
chronic HBV patients was assessed based on data from
western countries. Due to sample size issues, individual
treatment effects among prescribed oral antiviral medica-
tions were not examined. Previous studies showed that
treatment is cost-effective vs no treatment [26–30].
To ensure that economic evaluations are relevant, coun-
try-specific observational studies are necessary. Real-world
data analysis provides information about real-world clinical
practices across patient subgroups, which is difficult to
assess from trials, surveys, expert opinions and individual
hospital data. Recognizing the importance of real-world
data, Turkey invested in stronger information technology
systems. MEDULA, a nationwide integrated claims and uti-
lization management system, is the outcome of the invest-
ment. The use of the MEDULA data set allows researchers
Table 1 Oral antiviral vs pegylated interferon use
Oral antiviral
patients N = 9074
Pegylated interferon
patients N = 544
P-valueMean (N) SD (%) Mean (N) SD (%)
Age 45.28 13.06 42.19 13.33 <.0001
18–35 2216 24.42 189 34.74 <.0001
36–45 2316 25.52 121 22.24 0.0875
46–55 2524 27.82 144 26.47 0.4961
56–65 1460 16.09 70 12.87 0.0459
66+ 558 6.15 20 3.68 0.0184
Female 2919 32.17 216 39.71 0.0003
Region
East Anatolia 1170 12.89 69 12.68 0.8870
Southeastern Anatolia 752 8.29 76 13.97 <.0001
Marmara 1547 17.05 89 16.36 0.6781
Aegean 983 10.83 45 8.27 0.0604
Mediterranean 808 8.90 64 11.76 0.0240
Black Sea 1943 21.41 101 18.57 0.1149
Central Anatolia 1871 20.62 100 18.38 0.2093
Elixhauser Index Score
>2 5464 60.22 403 74.08 <.0001
Baseline diagnosis
Essential hypertension (Primary) 1297 14.29 72 13.24 0.4926
Type 2 diabetes mellitus 341 3.76 18 3.31 0.5914
Atherosclerotic heart disease of native coronary artery 155 1.71 15 2.76 0.0713
SD = standard deviation.
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to draw substantial knowledge regarding accurate results
of the total economic burden of HBV treatment on the
healthcare system in Turkey.
Although the economic burden of HBV has been increas-
ingly recognized, there are a limited number of studies
comparing costs associated with pegylated interferon thera-
pies and oral nucleotide analogue HBV medications for
European populations. However, in a cost-effectiveness
analysis of CHB in the United Kingdom [31], treatment
with pegylated interferon 2a compared to lamivudine was
found to provide improvement in health outcomes and
resulted in higher total healthcare costs (£3100).
Sensitivity analysis was performed to determine how the
study results would change if regression analysis was
applied instead of PSM. As costs were skewed, generalized
linear models (GLMs) with log link and gamma distribution
were applied. The results were no different from the PSM
analysis (P = 0.543).
The current study provides baseline data to evaluate
the economic effects of such treatments and assist future
CHB-related policy and analyses.
This study has several limitations. Claims data are gener-
ally collected for payment rather than research purposes.
Therefore, the presence of a diagnosis code on a medical
Table 2 Oral antiviral vs pegylated interferon use (matched)
Oral antiviral
patients N = 544
Pegylated interferon
patients N = 544
P-valueMean (N) SD (%) Mean (N) SD (%)
Age 41.74 13.24 42.19 13.33 0.5762
18–35 193 35.48 189 34.74 0.7994
36–45 130 23.90 121 22.24 0.5172
46–55 139 25.55 144 26.47 0.7297
56–65 59 10.85 70 12.87 0.3023
66+ 23 4.23 20 3.68 0.6406
Female 201 36.95 216 39.71 0.3496
Region
East Anatolia 72 13.24 69 12.68 0.7865
Southeastern Anatolia 71 13.05 76 13.97 0.6575
Marmara 83 15.26 89 16.36 0.6181
Aegean 47 8.64 45 8.27 0.8275
Mediterranean 67 12.32 64 11.76 0.7799
Black Sea 104 19.12 101 18.57 0.8161
Central Anatolia 100 18.38 100 18.38 1.0000
Elixhauser Index Score
≤2 130 23.90 141 25.92 0.4406
>2 414 76.10 403 74.08 0.4406
Baseline diagnosis
Essential (primary) hypertension 64 11.76 72 13.24 0.4633
Type 2 diabetes mellitus 16 2.94 18 3.31 0.7275
Atherosclerotic heart disease of native coronary artery 9 1.65 15 2.76 0.2155
SD = standard deviation.
Table 3 Risk-adjusted healthcare costs
Follow-up healthcare costs
Oral antiviral patients
N = 550
Pegylated interferon patients
N = 550
P-valueMean SD Mean SD
Inpatient €58.93 €304.94 €162.53 €1278.07 0.0664
Outpatient €334.89 €255.59 €588.86 €1307.13 <0.0001
Pharmacy €2554.74 €1617.89 €4965.90 €2556.66 <0.0001
Copays €10.23 €11.65 €11.86 €18.76 0.0863
Total costs €2958.80 €1724.09 €5729.16 €3434.98 <0.0001
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claim is not necessarily proof of the presence of disease. Diag-
noses may be incorrectly coded or included as a rule out cri-
teria rather than actual disease. To mitigate some of the
problems associated with ICD-10-CM codes, detailed quality
checks were applied, requiring the use of medication with
ICD-10-CM diagnosis codes. Secondly, the occurrence of a
drug prescription fill does not guarantee the actual con-
sumption of the drug by the patient. Therefore, study results
are biased to the extent that adherence to medication is
unevenly distributed among treatment options. Although
PSM was used to control for risk factors, the data did not
contain any measure of disease activity, health status or
patient lifestyle. Further studies that can link outcomes mea-
sures with clinical severity variables are warranted.
In conclusion, despite the availability of a safe and effec-
tive vaccine, CHB remains a public health concern in
Turkey, and little is known about the economic burden of
CHB in the country. This study is the first to provide data
representative of almost the entire Turkish population, and
the results reveal that oral antiviral treatment is cost-effec-
tive relative to pegylated interferon treatment. Using real-
world information, the current study provides valuable
information for policymakers to improve healthcare policy
in the future.
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